4.6 Review

PDZ domains at excitatory synapses: Potential molecular targets for persistent pain treatment

Journal

CURRENT NEUROPHARMACOLOGY
Volume 4, Issue 3, Pages 217-223

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157015906778019473

Keywords

PSD-93; PSD-95; NMDA receptors; AMPA receptors; trafficking; spinal cord; persistent pain; chronic pain

Funding

  1. NINDS NIH HHS [R01 NS044219] Funding Source: Medline

Ask authors/readers for more resources

Persistent pain. a common clinical condition, could be caused by inflammation, tissue injury secondary to trauma or surgery, and nerve injuries. It is often inadequately controlled by current treatments, such as opioids and nonsteroidal anti-inflammatory drugs. The PDZ (Postsynaptic density 95, Discs large, and Zonula occludens-1) domains are ubiquitous protein interaction modules often found among multi-protein signaling complexes at neuronal synapses. Recent preclinical research shows that targeted disruption of PDZ domain-mediated protein interaction among N-methyl-Daspartate (NMDA) receptor signaling complexes significantly attenuates the development and maintenance of persistent pain without affecting nociceptive responsiveness to acute pain. PDZ domains at excitatory synapses may be new molecular targets for prevention and treatment of persistent pain. Here, we illustrate expression and distribution of the PDZ domain-containing proteins associated with NMDA receptors in the pain-related regions of the central nervous system, review the evidence for their roles in persistent pain states, and discuss potential mechanisms by which these PDZ domain-containing proteins are involved in persistent pain.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available